Return to Home Incidence > Table > Interpret

Interpretation of Incidence Rates Data

Incidence Rate Report for Arizona by County

All Cancer Sites (All Stages^), 2016-2020

All Races (includes Hispanic), Both Sexes, Ages <50

Sorted by Count

Explanation of Column Headers

Objective - The objective of *** is from the Healthy People 2020 project done by the Centers for Disease Control and Prevention.

Incidence Rate (95% Confidence Interval) - The incidence rate is based upon 100,000 people and is an annual rate (or average annual rate) based on the time period indicated. Rates are age-adjusted by 5-year age groups to the 2000 U.S. standard million population.

Recent Trends - This is an interpretation of the AAPC/APC:

AAPC/APC (95% Confidence Interval) - the change in rate over time


Other Notes


Line by Line Interpretation of the Report


Arizona6


US (SEER+NPCR)1


Maricopa County6


Pima County6


Pinal County6


Yuma County6


Yavapai County6


Mohave County6


Cochise County6


Coconino County6


Navajo County6


Apache County6


Santa Cruz County6


Gila County6


Graham County6


La Paz County6


Greenlee County6




Notes:
Created by statecancerprofiles.cancer.gov on 03/19/2024 1:38 am.

State Cancer Registries may provide more current or more local data.
† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.
Rates and trends are computed using different standards for malignancy. For more information see malignant.html.

^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.


Source: SEER and NPCR data. For more specific information please see the table.
Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.

When displaying county information, the CI*Rank for the state is not shown because it's not comparable. To see the state CI*Rank please view the statistics at the US By State level.